Related Experiment Videos

Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment

H Uemura1, C Chang

  • 1George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, New York 14642, USA.

Endocrinology
|May 16, 1998
PubMed

Insights

The human TR3 orphan receptor is rapidly induced in prostate cancer cells during apoptosis. This receptor appears to play a role in modulating drug-induced prostate cancer cell death.

Area of Science:

  • Molecular Endocrinology
  • Cancer Biology
  • Prostate Cancer Research

Background:

  • The human TR3 orphan receptor, a steroid receptor superfamily member, is androgen-inducible in LNCaP cells.
  • TR3 expression is also induced in rat prostate following androgen ablation and apoptosis.

Purpose of the Study:

  • To investigate the role of the human TR3 orphan receptor in drug-induced apoptosis of prostate cancer cells.
  • To analyze the modulation of apoptosis by TR3 in prostate cancer models.

Main Methods:

  • Northern blot analysis to assess TR3 gene expression.
  • Transfection of prostate cancer cells (LNCaP and PC-3) with antisense TR3 or control vectors.
  • Treatment with calcium ionophore and etoposide to induce apoptosis.

Main Results:

  • Human TR3 orphan receptor expression was rapidly induced by calcium ionophore or etoposide in LNCaP and PC-3 cells.
  • Cells stably transfected with antisense TR3 required higher etoposide concentrations for cell death compared to controls.
  • This suggests TR3 plays a role in resistance to etoposide-induced apoptosis.

Conclusions:

  • The human TR3 orphan receptor is involved in the apoptotic process of prostate cancer cells.
  • TR3 may act as a modulator of drug-induced apoptosis in prostate cancer, potentially influencing treatment efficacy.

Related Concept Videos